Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05799248 · ClinicalTrials.gov registry record · Phase 3
Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
A Phase 3 study of Prostate Cancer, sponsored by MidLantic Urology.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 113
- Enrollment target
- 1
- Study location
NCT05799248: Recruiting Phase 3 study of Prostate Cancer, sponsored by MidLantic Urology.
NCT05799248 is a Phase 3 study of Prostate Cancer that is actively recruiting participants, run by MidLantic Urology. The registered enrollment target is 113 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05799248, a Phase 3 study of Prostate Cancer, is actively recruiting participants, sponsored by MidLantic Urology.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 113 participants
- Enrollment target
- 1
- Study location
Study Summary
Study Title: Role of rhPSMA-7.3 PET/CT imaging in men with High-Risk prostate cancer following conventional imaging and associated changes in medical management Protocol number: BED-IIT-437 Phase: 3b Sponsor: MidLantic Urology Funding Organization: Blue Earth Diagnostics Ltd Study Design: This is a Phase 3b, multi-center, single-arm, diagnostic imaging study designed to detect metastatic lesions in men diagnosed with high-risk prostate cancer.
Conditions Studied
Interventions
- DRUG rhPSMA-7.3 (18F)
Study Locations (1)
Pennsylvania
- MidLantic Urology - Bala-Cynwyd
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2023-04-27 |
| Est. Completion | 2024-05-28 |
| Phase | Phase 3 |
What NCT05799248 shows while recruiting
NCT05799248 is an interventional study that assigns participants to a tested intervention. The registered 113 participants enrollment target is mid-sized for trials with a published cap, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which rhPSMA-7.3 (18F) is the first listed.
NCT05799248 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05799248 about?
NCT05799248 is a clinical study titled "Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management". Study Title: Role of rhPSMA-7.3 PET/CT imaging in men with High-Risk prostate cancer following conventional imaging and associated changes in medical management Protocol number: BED-IIT-437 Phase: 3b Sponsor: MidLantic Urology Funding Organization: Blue Earth Diagnostics Ltd Study Design: This is a ...
What is the current status of trial NCT05799248?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 113 participants. The study started on 2023-04-27. Estimated completion is 2024-05-28.
What conditions does trial NCT05799248 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT05799248?
The interventions under investigation include: rhPSMA-7.3 (18F) (DRUG).
Who is sponsoring clinical trial NCT05799248?
This trial is sponsored by MidLantic Urology, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05799248 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05799248's enrollment target sits among peer trials
113 317th of 735 higher than 418 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00748254 · 113 participants
Laser-based Photoacoustic Tomography of Human Inflammatory Arthritis
- NCT04753190 · 113 participants · NA
Light Timing Study
- NCT07216105 · 113 participants · Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
- NCT07449715 · 113 participants
Respiration From Pleth Validation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI